Core Viewpoint - Yida Co., Ltd. plans to acquire 85% equity of Wanquan Biotechnology (Taizhou) Co., Ltd. from Wanquan Co., Ltd. for 24.565 million yuan, aiming to enhance its production capacity and product line in the fine chemical sector [1] Group 1 - The acquisition will make Wanquan Biotechnology a subsidiary of Yida Co., Ltd. [1] - The purpose of the acquisition is to leverage Wanquan's production experience and sales channel advantages [1] - The collaboration aims to promote the construction and investment of epoxy propylene (ethylene) derivatives in the fine chemical field [1] Group 2 - The transaction is expected to optimize Yida's capacity layout and enrich its product offerings [1] - The acquisition is intended to effectively meet downstream customer demands [1]

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan [1] Group 1: Acquisition Details - The acquisition involves the purchase of 85% equity in Wanqi Biotechnology (Taizhou) Co., Ltd. by the company's subsidiary, Taixing Yida Chemical Co., Ltd. [1] - The total investment for this acquisition is 24.565 million yuan [1] Group 2: Strategic Objectives - The acquisition is part of the company's strategy to promote high-end and refined product development [1] - The company intends to leverage Wanqi's years of production experience and sales channel advantages to advance the construction of epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - This move is expected to optimize the company's capacity layout, enrich its product line, and enhance production capabilities to effectively meet downstream customer demands [1]

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan, leveraging Wanqi's production experience and sales channels to optimize its capacity and product line [1] Group 1 - The acquisition amount is 24.565 million yuan [1] - The acquired company holds an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. [1] - The strategic goal is to promote high-end and refined product development [1] Group 2 - The collaboration will focus on the construction and investment in epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - The acquisition is expected to enhance the company's production capacity to effectively meet downstream customer demands [1] - The move is part of the company's strategy to optimize its capacity layout and enrich its product line [1]

2024年1至12月份，怡达股份的营业收入构成为：化工行业占比98.1%，其他业务占比1.9%。 截至发稿，怡达股份市值为24亿元。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 每经AI快讯，怡达股份（SZ 300721，收盘价：14.4元）11月28日晚间发布公告称，江苏怡达化学股份 有限公司控股子公司泰兴怡达化学有限公司以自有资金2456.5万元收购江苏万淇生物科技股份有限公司 持有的万淇生物科技（泰州）有限公司85%股权。本次交易完成后，标的公司成为公司控股孙公司。 （记者 曾健辉） ...

怡达股份公告，控股子公司泰兴怡达化学有限公司以自有资金2456.5万元收购江苏万淇生物科技股份有 限公司持有的万淇生物科技(泰州)有限公司85%股权。本次交易完成后，标的公司成为公司控股孙公 司。 ...

证券代码：300721 证券简称: 怡达股份 公告编号：2025-037 江苏怡达化学股份有限公司 关于控股子公司收购股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、交易概述 1、 江苏怡达化学股份有限公司（以下简称"怡达股份"、"公司"）控股 子公司泰兴怡达化学有限公司（以下简称"泰兴怡达"）以自有资金 2,456.50 万元收购江苏万淇生物科技股份有限公司（以下简称"万淇股份"）持有的万淇 生物科技（泰州）有限公司（以下简称"标的公司"）85%股权。本次交易完成 后，标的公司成为公司控股孙公司。本次收购事项不构成关联交易，亦不构成《上 市公司重大资产重组管理办法》规定的重大资产重组事项。 2、 公司于 2025 年 11 月 28 日召开了第五届董事会第七次会议，审议通过 了《关于控股子公司收购股权的议案》。根据《深圳证券交易所创业板股票上市 规则》以及《公司章程》等有关规定，本次收购事项无需提交股东会审议。 | 公司名称 | 江苏万淇生物科技股份有限公司 | | --- | --- | | 企业类型 | 股份有限公司（非上市） | | 注 ...

证券代码：300721 证券简称:怡达股份 公告编号：2025-036 第五届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏怡达化学股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日上 午 9:00 在公司会议室召开第五届董事会第七次会议，本次会议由刘准董事长主 持，本次会议应出席会议的董事为 7 人，实际出席会议董事 7 人，公司部分高级 管理人员列席了会议。本次会议的召开符合《公司法》及《公司章程》中有关董 事会召开的有关规定。 二、董事会会议审议情况 1、 《关于控股子公司收购股权的议案》 江苏怡达化学股份有限公司 经与会董事认真审议并通过投票表决的方式通过了如下决议： 基于公司战略发展和经营发展需要，为优化公司产业布局，提高公司竞争力， 经交易双方友好协商，公司控股子公司泰兴怡达拟以现金方式收购江苏万淇生物 科技股份有限公司持有的万淇生物科技（泰州）有限公司 85%股权，股权转让价 格为 2,456.50 万元。本次交易完成后，泰兴怡达将持有万淇生物科技（泰州） 有限公司 85% ...

格隆汇11月24日丨怡达股份(300721.SZ)在投资者互动平台表示，公司暂无扩产环氧丙烷产能的计划。 ...

Core Viewpoint - Yida Co., Ltd. announced the completion of the share reduction plan implemented by its director and CFO, Ms. Sun Yinfeng [2] Summary by Relevant Sections - Company Announcement - Yida Co., Ltd. has received a notice from its director and CFO regarding the completion of the share reduction plan [2]

Core Insights - Yida Co., Ltd. (300721.SZ) released its Q3 2025 financial report on October 25, 2025, indicating a total institutional holding of 1.1509 million shares, representing 0.70% of the total share capital [1] - The institutional holding ratio decreased by 0.10 percentage points compared to the previous quarter [1] Institutional Investors - As of October 24, 2025, there is one institutional investor holding shares in Yida Co., Ltd., which is Wuxi Shenyin Investment Enterprise (Limited Partnership) [1] - The total institutional holding ratio stands at 0.70% [1] Public Funds - In this reporting period, seven public funds were disclosed, which were not reported in the previous quarter [1] - Notable public funds include Zhongzheng 2000, Western Gain Quantitative Preferred One-Year Holding Mixed A, Southern Zhongzheng 2000 ETF, and others [1]